PC786 in phase 1 study

Pulmocide  a clinical-stage company today announces the successful dosing of PC786 in a phase 1 study. PC786 is a potent inhibitor of RSV L polymerase which is delivered by inhaled administration for the treatment of RSV A and B […]

19 July 2017

Read more

Pulmocide presented at RSV16 in Patagonia, Argentina

Pulmocide gave an oral presentation at RSV16 (10th International respiratory syncytial virus symposium), held September 28 – October 01, 2016 in Patagonia, Argentina. Title was: Characterization of the non-nucleoside polymerase […]

04 October 2016

Read more